Industry news that matters to you.  Learn more

Biomarker Discovery Center Established at UMDNJ-School of Osteopathic Medicine

Following recent discoveries by its researchers that could significantly change the diagnosis and treatment of a number of diseases, the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine has established the Biomarker Discovery Center on its Stratford campus. The new center will be under the direction of Robert Nagele, PhD, professor of Medicine at the medical school’s New Jersey Institute for Successful Aging. Dr. Nagele’s published research includes recent findings that show how blood-borne biomarkers can potentially be used to diagnose early stages of Alzheimer’s and Parkinson’s diseases.

Ballenger Trust Selects the Myelin Repair Foundation to Advance Myelin Repair Therapeutic Development for Multiple Sclerosis

The Myelin Repair Foundation (MRF) recently announced the support of the Ballenger Trust to accelerate the development of myelin repair therapeutics for multiple sclerosis (MS). The $700,000 gift will provide support for the MRF biomarker project, myelin repair research in human brain tissue and a repurposing opportunity. With the Ballenger Trust’s support, these critical projects will accelerate the Myelin Repair Foundation’s research to develop a myelin repair therapeutic for multiple sclerosis.

Ezose Sciences Forms Alliance with Fast Forward to Discover Biomarkers to Diagnose Multiple Sclerosis

Ezose Sciences Inc. today announced an alliance with Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, to use Ezose’s GlycanMap technology in the discovery of biomarkers to help diagnose multiple sclerosis (MS) and improve disease management.

Scientists at Scripps Research Develop Novel Technology to Identify Biomarkers for Ulcerative Colitis

Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon.

Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a collaboration with Biogen Idec (NASDAQ: BIIB) to identify microRNAs as biomarkers for multiple sclerosis (MS). Under the transaction, Biogen Idec will make an investment in Regulus in addition to upfront and milestone payments. The key objective of the collaboration is to identify microRNA biomarkers in the blood of patients with MS. Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.